Summary
76.40 -0.36(-0.46%)02/12/2026
Agree Realty Corporation (ADC)
ADC reported last earnings on 2025-10-21 after the market. An EPS of $1.1 was observed compared to an estimated EPS of $1.08, resulting in a surprise value of $0.02. A revenue of $183 million was observed compared to an estimated revenue of $190 million, resulting in a surprise value of $-7 Million.
Agree Realty Corporation (ADC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.46 | 5.26 | 5.79 | 3.01 | 2.48 | 5.48 | 38.93 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Sell |
| ROA | Neutral |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 76.40 | |
| Open | 77.13 | |
| High | 78.01 | |
| Low | 76.13 | |
| Volume | 1,560,796 | |
| Change | -0.36 | |
| Change % | -0.46 | |
| Avg Volume (20 Days) | 838,484 | |
| Volume/Avg Volume (20 Days) Ratio | 1.86 | |
| 52 Week Range | 67.31 - 77.72 | |
| Price vs 52 Week High | -1.70% | |
| Price vs 52 Week Low | 13.50% | |
| Range | -2.31 | |
| Gap Up/Down | 0.19 | |
Profitibility | ||
| Market Capitalization (Mln) | 7,909 | |
| Revenue per share | 6.2635 | |
| Net Income per share | 1.7330 | |
| Dividend Yield | 0.0403 | |
| Dividend Share | 309.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 44.2866 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
02/12 11:32 EST - forbes.com
2 Triple Net Lease REITs Set To Gain As Interest Rates Tick Lower
Real estate investment trusts (REITs) tend to shine when there is a lid on interest rates. And that rate top is secure, for reasons we'll review shortly.
2 Triple Net Lease REITs Set To Gain As Interest Rates Tick Lower
Real estate investment trusts (REITs) tend to shine when there is a lid on interest rates. And that rate top is secure, for reasons we'll review shortly.
02/12 07:46 EST - 247wallst.com
Retirees Rely On These 5 Safe High-Yield Monthly Pay Dividend Stocks
Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
Retirees Rely On These 5 Safe High-Yield Monthly Pay Dividend Stocks
Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
02/11 14:24 EST - seekingalpha.com
Agree Realty Corporation (ADC) Q4 2025 Earnings Call Transcript
Agree Realty Corporation (ADC) Q4 2025 Earnings Call Transcript
Agree Realty Corporation (ADC) Q4 2025 Earnings Call Transcript
Agree Realty Corporation (ADC) Q4 2025 Earnings Call Transcript
02/11 08:45 EST - globenewswire.com
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline
CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline
CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy
02/10 20:00 EST - zacks.com
Agree Realty (ADC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Agree Realty (ADC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Agree Realty (ADC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Agree Realty (ADC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
02/10 18:25 EST - zacks.com
Agree Realty (ADC) Q4 FFO and Revenues Top Estimates
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.11 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to FFO of $1.04 per share a year ago.
Agree Realty (ADC) Q4 FFO and Revenues Top Estimates
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.11 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to FFO of $1.04 per share a year ago.
02/10 16:05 EST - businesswire.com
Agree Realty Corporation Reports Fourth Quarter and Full Year 2025 Results
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter and full year ended December 31, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Fourth Quarter 2025...
Agree Realty Corporation Reports Fourth Quarter and Full Year 2025 Results
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter and full year ended December 31, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Fourth Quarter 2025...
02/10 03:15 EST - newsfilecorp.com
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on...
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on...
02/07 03:18 EST - seekingalpha.com
F5: Security Incident Impact And Outlook
F5 leverages high-performance ADC products, robust software growth, and partnerships like NVIDIA to capitalize on AI and hybrid multi-cloud trends. Despite the FY25 cybersecurity breach, F5's recurring revenue base and swift mitigation steps limit long-term impact; near-term growth slows but...
F5: Security Incident Impact And Outlook
F5 leverages high-performance ADC products, robust software growth, and partnerships like NVIDIA to capitalize on AI and hybrid multi-cloud trends. Despite the FY25 cybersecurity breach, F5's recurring revenue base and swift mitigation steps limit long-term impact; near-term growth slows but...
02/06 16:47 EST - benzinga.com
Why Agree Realty Guided Lower for 2026, Despite a Strong Balance Sheet
I spent most of last month pulling apart net lease credit structures — Realty Income's A- rating, NNN REIT's longer-dated debt stack, the mechanics of how buffer distance from the BBB- cliff translates into real-world resilience. Each time, the question was the same: how much room does this...
Why Agree Realty Guided Lower for 2026, Despite a Strong Balance Sheet
I spent most of last month pulling apart net lease credit structures — Realty Income's A- rating, NNN REIT's longer-dated debt stack, the mechanics of how buffer distance from the BBB- cliff translates into real-world resilience. Each time, the question was the same: how much room does this...
02/06 11:09 EST - seekingalpha.com
Agree Realty: Planting Seeds Today To Live In The Shade Tomorrow
Agree Realty stands out among net lease REITs for its disciplined low-leverage strategy and focus on high-quality national tenants. ADC's innovative ground lease platform and creative portfolio management differentiate it from faster-growing peers like O. Both ADC common and preferred shares earn a...
Agree Realty: Planting Seeds Today To Live In The Shade Tomorrow
Agree Realty stands out among net lease REITs for its disciplined low-leverage strategy and focus on high-quality national tenants. ADC's innovative ground lease platform and creative portfolio management differentiate it from faster-growing peers like O. Both ADC common and preferred shares earn a...
02/05 16:05 EST - businesswire.com
Agree Realty Declares Monthly Common and Preferred Dividends
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of...
Agree Realty Declares Monthly Common and Preferred Dividends
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of...
02/04 07:00 EST - businesswire.com
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug...
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug...
02/02 16:05 EST - prnewswire.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's...
01/27 18:09 EST - seekingalpha.com
Agree Realty: 4.3% Yield With Rent Recapture Catalyst
Agree Realty is positioned for future outperformance after recent underperformance, driven by conservative leverage and high-quality assets. ADC's 67% investment-grade tenant base, focus on freestanding assets, and ground leases enhance portfolio quality and recession resistance. With 6.8% YoY AFFO...
Agree Realty: 4.3% Yield With Rent Recapture Catalyst
Agree Realty is positioned for future outperformance after recent underperformance, driven by conservative leverage and high-quality assets. ADC's 67% investment-grade tenant base, focus on freestanding assets, and ground leases enhance portfolio quality and recession resistance. With 6.8% YoY AFFO...
01/26 08:45 EST - globenewswire.com
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology's most challenging and valuable solid tumor targets, CEACAM5 TAMPA and...
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology's most challenging and valuable solid tumor targets, CEACAM5 TAMPA and...
01/26 06:12 EST - defenseworld.net
Agree Realty Corporation $ADC Shares Bought by Strs Ohio
Strs Ohio raised its stake in shares of Agree Realty Corporation (NYSE: ADC) by 79.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,492 shares of the real estate investment trust's stock after...
Agree Realty Corporation $ADC Shares Bought by Strs Ohio
Strs Ohio raised its stake in shares of Agree Realty Corporation (NYSE: ADC) by 79.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,492 shares of the real estate investment trust's stock after...
01/23 17:09 EST - seekingalpha.com
3 Monthly Dividend Payers I'm Buying Right Now
3 Monthly Dividend Payers I'm Buying Right Now
3 Monthly Dividend Payers I'm Buying Right Now
3 Monthly Dividend Payers I'm Buying Right Now
01/22 10:00 EST - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
01/20 16:37 EST - globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Market News
×
Loading news…